ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Medartis (MED.SW)
Medartis stock price today, ATLAS forecast and fair value
Healthcare · Medical Devices · SIX Swiss Exchange · Switzerland
CHF 94.70▲ +1.18%
Prices as of Oct 27, 2026 · CHF
Chance of rising in 1 month
51%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Medartis in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Medartis
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Medartis a 51% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between CHF 89.58 and CHF 100.37; in 9 out of 10, between CHF 80.99 and CHF 111.02. Estimated annual volatility is 31%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- CHF 1.0B
- Market cap (USD)
- $1.3B
- P/E ratio
- 73.1
- 52-week high
- CHF 97.50
- 52-week low
- CHF 70.60
- Revenue (12 months)
- CHF 307M
- Gross margin
- 77.5%
- Operating margin
- 8.9%
- Net margin
- 4.9%
- Beta
- 1.14
What this means
ATLAS does not publish a fair value for MED.SW right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks MED.SW has traded between CHF 70.60 and CHF 97.50. Today it is 2.9% below that high and 34% above its low.
On the business: net margin is 4.9%; it trades at 73.1 times earnings.
Its beta is 1.14: it moves roughly in line with the market.
About the company
Medartis Holding AG, a medical device company, engages in the development, manufacturing, and sales of implant solutions worldwide.
Want to see everything about Medartis?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Medartis do?
Medartis Holding AG, a medical device company, engages in the development, manufacturing, and sales of implant solutions worldwide.
What is the chance MED.SW goes up next month?
51%: close to a coin flip. In half of the simulated outcomes, MED.SW ends the month between CHF 89.58 and CHF 100.37.
How big is Medartis and what is its P/E ratio?
Medartis's market capitalization is CHF 1.0B. Its price-to-earnings (P/E) ratio is 73.1: you pay CHF 73.1 for each CHF 1.00 of yearly earnings.
How volatile is MED.SW?
ATLAS estimates annual volatility at 31%. In a typical month, half of the outcomes end between CHF 89.58 and CHF 100.37.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer